Logo image of CEMI

CHEMBIO DIAGNOSTICS INC (CEMI) Stock Fundamental Analysis

USA - NASDAQ:CEMI - US1635722093 - Common Stock

0.455 USD
+0 (+0.22%)
Last: 4/27/2023, 8:20:06 PM
0.4311 USD
-0.02 (-5.25%)
After Hours: 4/27/2023, 8:20:06 PM
Fundamental Rating

1

CEMI gets a fundamental rating of 1 out of 10. The analysis compared the fundamentals against 189 industry peers in the Health Care Equipment & Supplies industry. CEMI may be in some trouble as it scores bad on both profitability and health. CEMI is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

0

1. Profitability

1.1 Basic Checks

CEMI had negative earnings in the past year.
In the past year CEMI has reported a negative cash flow from operations.
CEMI had negative earnings in each of the past 5 years.
CEMI had a negative operating cash flow in each of the past 5 years.
CEMI Yearly Net Income VS EBIT VS OCF VS FCFCEMI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 0 -10M -20M -30M

1.2 Ratios

The profitability ratios for CEMI are negative, so there is not much use analyzing them.
Industry RankSector Rank
ROA N/A
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
CEMI Yearly ROA, ROE, ROICCEMI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 -20 -40 -60 -80 -100

1.3 Margins

Looking at the Gross Margin, with a value of 22.10%, CEMI is doing worse than 78.20% of the companies in the same industry.
In the last couple of years the Gross Margin of CEMI has declined.
The Profit Margin and Operating Margin are not available for CEMI so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 22.1%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-14.23%
GM growth 5Y-13.7%
CEMI Yearly Profit, Operating, Gross MarginsCEMI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 0 20 -20 40 -40 -60

2

2. Health

2.1 Basic Checks

CEMI does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for CEMI has been increased compared to 1 year ago.
Compared to 1 year ago, CEMI has a worse debt to assets ratio.
CEMI Yearly Shares OutstandingCEMI Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 10M 20M 30M
CEMI Yearly Total Debt VS Total AssetsCEMI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 20M 40M 60M

2.2 Solvency

Based on the Altman-Z score of -3.34, we must say that CEMI is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -3.34, CEMI is doing worse than 65.40% of the companies in the same industry.
A Debt/Equity ratio of 0.00 indicates that CEMI is not too dependend on debt financing.
CEMI's Debt to Equity ratio of 0.00 is fine compared to the rest of the industry. CEMI outperforms 65.88% of its industry peers.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -3.34
ROIC/WACCN/A
WACC9.13%
CEMI Yearly LT Debt VS Equity VS FCFCEMI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 0 20M -20M

2.3 Liquidity

A Current Ratio of 1.23 indicates that CEMI should not have too much problems paying its short term obligations.
Looking at the Current ratio, with a value of 1.23, CEMI is doing worse than 82.94% of the companies in the same industry.
CEMI has a Quick Ratio of 1.04. This is a normal value and indicates that CEMI is financially healthy and should not expect problems in meeting its short term obligations.
CEMI's Quick ratio of 1.04 is on the low side compared to the rest of the industry. CEMI is outperformed by 78.67% of its industry peers.
Industry RankSector Rank
Current Ratio 1.23
Quick Ratio 1.04
CEMI Yearly Current Assets VS Current LiabilitesCEMI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 10M 20M 30M 40M 50M

2

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 45.07% over the past year.
The Revenue has been growing slightly by 3.57% in the past year.
The Revenue has been growing by 15.57% on average over the past years. This is quite good.
EPS 1Y (TTM)45.07%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%94.95%
Revenue 1Y (TTM)3.57%
Revenue growth 3Y12.85%
Revenue growth 5Y15.57%
Sales Q2Q%-49.72%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
CEMI Yearly Revenue VS EstimatesCEMI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 10M 20M 30M 40M
CEMI Yearly EPS VS EstimatesCEMI Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 -0.2 -0.4 -0.6 -0.8 -1

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for CEMI. In the last year negative earnings were reported.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CEMI Price Earnings VS Forward Price EarningsCEMI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CEMI Per share dataCEMI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

0

5. Dividend

5.1 Amount

CEMI does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

CHEMBIO DIAGNOSTICS INC

NASDAQ:CEMI (4/27/2023, 8:20:06 PM)

After market: 0.4311 -0.02 (-5.25%)

0.455

+0 (+0.22%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)03-09 2023-03-09
Earnings (Next)05-09 2023-05-09
Inst Owners0%
Inst Owner Change0%
Ins Owners7.8%
Ins Owner Change0%
Market Cap16.71M
Revenue(TTM)49.52M
Net Income(TTM)-23290650
Analysts43.33
Price Target8.16 (1693.41%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly Dividend0
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.34
P/FCF N/A
P/OCF N/A
P/B 0.94
P/tB 0.94
EV/EBITDA N/A
EPS(TTM)-0.75
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.39
FCFYN/A
OCF(TTM)-0.35
OCFYN/A
SpS1.35
BVpS0.48
TBVpS0.48
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA N/A
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 22.1%
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-14.23%
GM growth 5Y-13.7%
F-Score3
Asset Turnover0.79
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 56.84%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.23
Quick Ratio 1.04
Altman-Z -3.34
F-Score3
WACC9.13%
ROIC/WACCN/A
Cap/Depr(3y)91.56%
Cap/Depr(5y)127.18%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)45.07%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%94.95%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)3.57%
Revenue growth 3Y12.85%
Revenue growth 5Y15.57%
Sales Q2Q%-49.72%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y15.04%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y56.8%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y58.9%
OCF growth 3YN/A
OCF growth 5YN/A

CHEMBIO DIAGNOSTICS INC / CEMI FAQ

What is the ChartMill fundamental rating of CHEMBIO DIAGNOSTICS INC (CEMI) stock?

ChartMill assigns a fundamental rating of 2 / 10 to CEMI.


What is the valuation status for CEMI stock?

ChartMill assigns a valuation rating of 2 / 10 to CHEMBIO DIAGNOSTICS INC (CEMI). This can be considered as Overvalued.


Can you provide the profitability details for CHEMBIO DIAGNOSTICS INC?

CHEMBIO DIAGNOSTICS INC (CEMI) has a profitability rating of 1 / 10.